National Registry for Gene and Cell Therapies Germany

– central structure for collecting application data of innovative therapies

Successful Establishment of the National Registry for Gene and Cell Therapies Germany – A Central Structure for Collecting Real-World Data on Innovative Therapies

 

On 30 June 2025, leading medical societies and institutions founded the association “National Registry for Gene and Cell Therapies Germany” (Nationales Gen- und Zelltherapieregister Deutschland e. V. - nGCT-R). The founding organizations include the German Society for Hematology and Oncology (DGHO), the German Society for Pediatrics and Adolescent Medicine (DGKJ), the Society for Neuropediatrics (GNP), the Society of Thrombosis and Haemostasis Research (GTH), the German Society for Gene Therapy (DG-GT), the Berlin Institute of Health (BIH), and the INTEGRATE-ATMP consortium. The association was registered in the Register of Associations on 11 December 2025.

The objective of the nGCT-R is to establish and sustain a central digital registry infrastructure for the indication-independent collection of data on gene and cell therapies. This will create a reliable data basis for the systematic evaluation of the effectiveness and safety of these innovative therapies, thereby strengthening research, healthcare delivery, and patient safety.

With the establishment of the association, the structures developed within the Innovation Fund project INTEGRATE-ATMP will be continued on a sustainable basis. In the future, the registry is intended to expand to additional medical fields and to involve relevant stakeholders from government, health insurers, regulatory authorities, and industry in a structured manner.

​

A joint press release by the participating medical societies and the BIH was issued on 21 January 2026.